Molecular mechanism of vacuolar formation associated with cell death induced by CDK4/6 inhibitor abemaciclib

被引：0
|
作者：
Hino, Hirotsugu [1 ]
Tanaka, Yoshinori [2 ]
Okimoto, Tomoya [1 ]
Ikeda, Toshikatsu [1 ]
Hara, Tomoyo [1 ]
Takeya, Kosuke [2 ]
Takano, Naoharu [3 ]
Hiramoto, Masaka [3 ]
Aizawa, Shin [1 ]
Miyazawa, Keisuke [3 ]
Eto, Masumi [2 ]
Hirai, Shuichi [1 ]
机构：
[1] Nihon Univ, Div Anat Sci, Dept Funct Morphol, Sch Med, Tokyo, Japan
[2] Okayama Univ Sci, Dept Vet Med, Biochem Unit, Okayama, Japan
[3] Tokyo Med Univ, Dept Biochem, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3317
引用
收藏
页码：1741 / 1741
页数：1
相关论文
共 50 条
  • [1] CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2021, 112 : 900 - 900
  • [2] Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
    Eskiler, Gamze Guney
    Ozkan, Asuman Deveci
    Haciefendi, Ayten
    Bilir, Cemil
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [3] Different mechanism of CDK4/6 inhibitor resistance between ribociclib and abemaciclib
    Iida, Masafumi
    Toyosawa, Daichi
    Nakamura, Misato
    Tokuda, Emi
    Niwa, Toshifumi
    Yoshida, Ryuichi
    Ishida, Takanori
    Hayashi, Shin-ichi
    CANCER RESEARCH, 2020, 80 (04)
  • [4] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [5] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6
    Gong, Xuegian
    Chio, Li -Chun
    Lallena, MaryJo
    Merzoug, Farhana
    Chu, Shaoyou
    Webster, Yue
    Dempsey, Jack
    Ma, Xiwen
    De Dios, Alfonso
    Beckman, Richard
    Buchanan, Sean G.
    CANCER RESEARCH, 2015, 75
  • [7] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [8] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [9] Lysosome-targeted cytocidal effect of CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2018, 109 : 1026 - 1026
  • [10] Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
    Liang, Muh-Lii
    Chen, Chun-Han
    Liu, Yun-Ru
    Huang, Man-Hsu
    Lin, Yu-Chen
    Wong, Tai-Tong
    Lin, Sey-En
    Chu, Shing-Shiung
    Ding, Yi-Huei
    Hsieh, Tsung-Han
    CANCERS, 2020, 12 (12) : 1 - 17
12345